PDF下载 ( 2024 KB)
Influence of baseline HBV DNA level on the clinical outcome of patients with compensated hepatitis B cirrhosis after antiviral therapy
-
摘要: 目的分析基线HBV DNA水平对代偿期乙型肝炎肝硬化患者抗病毒治疗后临床转归的影响。方法选取首都医科大学附属北京友谊医院肝病中心2005年-2015年代偿期乙型肝炎肝硬化患者106例,给予核苷和核苷酸类药物抗病毒治疗,对患者进行前瞻性随访观察3年。按治疗前HBV DNA水平将患者分为3组,即HBV DNA<105IU/ml组、105107IU/ml组和>107IU/ml组。比较3组患者基线特征、抗病毒治疗疗效及肝脏相关终点事件（LREs）发生率。组间比较采用重复测量资料的方差分析或Friedman Test检验;计数资料组间比较采用χ2检验。采用Kaplan-Meier法计算LREs发生率并绘制生存曲线,各组之间的比较采用log-rank对数秩检验。结果 3组患者在年龄、性别、HBeAg、生化指标、肝脏硬度及CTP评分上差异均无统计学意义（P值均>0.05）。HBV DNA水平随时间的变化趋势差异有统计学意义（F=8.35,P<0.05）;3组间比较HBV DNA水平的变化差异也有统计学意义（F=13.95,P<...Abstract: Objective To investigate the influence of baseline HBV DNA level on the clinical outcome of patients with compensated hepatitis B cirrhosis after antiviral therapy. Methods A total of 106 patients with compensated hepatitis B cirrhosis who were treated in Liver Research Center, Beijing Friendship Hospital, Capital Medical University from 2005 to 2015 were enrolled and were given antiviral therapy with nucleos ( t) ide analogues. A three-year prospective follow-up was performed for all patients. According to the baseline HBV DNA level, the patients were divided into HBV DNA < 105 IU/ml group, 105-107 IU/ml group, and > 107 IU/ml group. The three groups were compared in terms of baseline characteristics, outcome of antiviral therapy, and incidence rate of liver-related events ( LREs) . A repeated-measures analysis of variance or the Friedman rank sum test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to calculate the incidence rates of LREs and plot survival curves, and the log-rank test was used for comparison between groups. Results There were no significant differences between the three groups in age, sex, HBeAg, biochemical parameters, liver stiffness, and Child-Turcotte-Pugh score ( all P >0. 05) . There were significant differences between the three groups in the change trend of HBV DNA level ( F = 8. 35, P < 0. 05) and the degree of such change ( F = 13. 95, P < 0. 05) . At 6 months of treatment, all three groups had a significant reduction in HBV DNA level, and the HBV DNA < 105 IU/ml group and the 105-107 IU/ml group achieved a median HBV DNA level of below the limit of detection, while the HBV DNA > 107 IU/ml group achieved such a level at 12 months of treatment. At 12 and 24 months of treatment, there was no significant difference in HBV DNA clearance rate between the three groups ( χ2= 5. 97 and 6. 84, both P > 0. 05) ; at 36 months of treatment, there was a significant difference in HBV DNA clearance rate between the three groups ( 95. 7% vs 88. 0% vs 77. 8%, χ2= 12. 75, P < 0. 05) . There was no significant difference in the incidence rate of LREs between the three groups ( P > 0. 05) . Conclusion Patients with compensated hepatitis B cirrhosis have a significant reduction in HBV DNA level after antiviral therapy. Although patients with a high level of replication have slow virologic response, baseline HBV DNA level has no influence on the incidence rate of LREs within 3 years of antiviral therapy.
-
Key words:
- liver cirrhosis /
- hepatitis B, chronic /
- HBV DNA /
- antiviral therapy
-
[1]CHEN CF, LEE WC, YANG HI, et al.Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma[J].Gastroenterology, 2011, 141 (4) :1240-1248. [2]HOU JL, WANG GQ, WANG FS, et al.Guideline of prevention and treatment for chronic hepatitis B (2015 update) [J].J Clin Transl Hepatol, 2017, 5 (4) :297-318. [3]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98. [4]European Association for the Study of the Liver, European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398. [5]TERRAULT NA, LOK ASF, MCMAHON BJ, et al.Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD2018 hepatitis B guidance[J].Hepatology, 2018, 67 (4) :1560-1599. [6]WEI L, JIA JD, WENG XH, et al.Treating chronic hepatitis B virus:Chinese physicians'awareness of the 2010 guidelines[J].World J Hepatol, 2016, 8 (18) :762-769. [7]SHAN S, CUI FQ, JIA JD.How to control highly endemic hepatitis B in Asia[J].Liver Int, 2018, 38 (Suppl 1) :122-125. [8]BENVEGNUL, GIOS M, BOCCATO S, et al.Natural history of compensated viral cirrhosis:A prospective study on the incidence and hierarchy of major complications[J].Gut, 2004, 53 (5) :744-749. [9]SINN DH, LEE J, GOO J, et al.Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load[J].Hepatology, 2015, 62 (3) :694-701. [10]KIM JH, SINN DH, KANG W, et al.Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J].Hepatology, 2017, 66 (2) :335-343. [11]SCHIFF ER, LEE SS, CHAO YC, et al.Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J].Clin Gastroenterol Hepatol, 2011, 9 (3) :274-276. [12]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open-label follow-up study[J].Lancet, 2013, 381 (9865) :468-475. [13]XU Y, WU XN, SHI YW, et al.Baseline hepatitis B virus DNA level is a promising factor for predicting the 3 (rd) month virological response to entecavir therapy:A study of strict defined hepatitis B virus induced cirrhosis[J].Chin Med J (Engl) , 2015, 128 (14) :1867-1872. -
本文二维码
计量
- 文章访问数: 2122
- HTML全文浏览量: 40
- PDF下载量: 414
- 被引次数: 0
下载:
